Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease

Completed · Not applicable

Conditions studied: Pyoderma Gangrenosum, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease

In brief

Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication. Visits occur every 2 weeks initially, then every 1-2 months later in the study.

Key facts

Study ID

NCT00791557

Run by

University Hospitals Cleveland Medical Center

People needed

2

Starts

2008-10-01

Expected to finish

2010-02-01

Last updated by the study team

2016-11-02

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must Be ages 18-75
• Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum
• Must never have received Infliximab for the treatment of pyoderma gangrenosum

You may not qualify if…

• Have had any previous treatment with monoclonal antibodies other than infliximab used to treat IBD or antibody fragments.
• Have a history of serious infections

Where it is running

• University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.